Report Thumbnail
Product Code LP0914110472ATS
Published Date 2023/2/16
LP Information
English71 PagesGlobal

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Growth 2023-2029 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0914110472ATS◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/2/16
LP Information
English 71 PagesGlobal

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Growth 2023-2029 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.
LPI (LP Information)' newest research report, the “Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Forecast” looks at past sales and reviews total world Idiopathic Pulmonary Fibrosis (IPF) Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Idiopathic Pulmonary Fibrosis (IPF) Drug sales for 2023 through 2029. With Idiopathic Pulmonary Fibrosis (IPF) Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Idiopathic Pulmonary Fibrosis (IPF) Drug industry.
This Insight Report provides a comprehensive analysis of the global Idiopathic Pulmonary Fibrosis (IPF) Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Idiopathic Pulmonary Fibrosis (IPF) Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Idiopathic Pulmonary Fibrosis (IPF) Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Idiopathic Pulmonary Fibrosis (IPF) Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Idiopathic Pulmonary Fibrosis (IPF) Drug.
The global Idiopathic Pulmonary Fibrosis (IPF) Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Idiopathic Pulmonary Fibrosis (IPF) Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Idiopathic Pulmonary Fibrosis (IPF) Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Idiopathic Pulmonary Fibrosis (IPF) Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Idiopathic Pulmonary Fibrosis (IPF) Drug players cover American Lung Association, Roche, Genentech and Fierce Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Idiopathic Pulmonary Fibrosis (IPF) Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Nintedanib
Pirfenidone
Segmentation by application
Hospital
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
American Lung Association
Roche
Genentech
Fierce Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Idiopathic Pulmonary Fibrosis (IPF) Drug market?
What factors are driving Idiopathic Pulmonary Fibrosis (IPF) Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Idiopathic Pulmonary Fibrosis (IPF) Drug market opportunities vary by end market size?
How does Idiopathic Pulmonary Fibrosis (IPF) Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats

  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Idiopathic Pulmonary Fibrosis (IPF) Drug by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Idiopathic Pulmonary Fibrosis (IPF) Drug by Country/Region, 2018, 2022 & 2029
    • 2.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Segment by Type
      • 2.2.1 Nintedanib
      • 2.2.2 Pirfenidone
    • 2.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type
      • 2.3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Price by Type (2018-2023)
    • 2.4 Idiopathic Pulmonary Fibrosis (IPF) Drug Segment by Application
      • 2.4.1 Hospital
      • 2.4.2 Clinics
      • 2.4.3 Others
    • 2.5 Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application
      • 2.5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Price by Application (2018-2023)

  • 3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug by Company

    • 3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Breakdown Data by Company
      • 3.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales by Company (2018-2023)
      • 3.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Company (2018-2023)
    • 3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Company (2018-2023)
      • 3.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Company (2018-2023)
    • 3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Price by Company
    • 3.4 Key Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Product Location Distribution
      • 3.4.2 Players Idiopathic Pulmonary Fibrosis (IPF) Drug Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion

  • 4 World Historic Review for Idiopathic Pulmonary Fibrosis (IPF) Drug by Geographic Region

    • 4.1 World Historic Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Growth
    • 4.4 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Growth
    • 4.5 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Growth
    • 4.6 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Growth

  • 5 Americas

    • 5.1 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country
      • 5.1.1 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2018-2023)
      • 5.1.2 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2018-2023)
    • 5.2 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type
    • 5.3 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil

  • 6 APAC

    • 6.1 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region
      • 6.1.1 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region (2018-2023)
      • 6.1.2 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region (2018-2023)
    • 6.2 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type
    • 6.3 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan

  • 7 Europe

    • 7.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug by Country
      • 7.1.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2018-2023)
      • 7.1.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2018-2023)
    • 7.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type
    • 7.3 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia

  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug by Country
      • 8.1.1 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type
    • 8.3 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries

  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends

  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug
    • 10.3 Manufacturing Process Analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug
    • 10.4 Industry Chain Structure of Idiopathic Pulmonary Fibrosis (IPF) Drug

  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Distributors
    • 11.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Customer

  • 12 World Forecast Review for Idiopathic Pulmonary Fibrosis (IPF) Drug by Geographic Region

    • 12.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size Forecast by Region
      • 12.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Forecast by Region (2024-2029)
      • 12.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Forecast by Type
    • 12.7 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Forecast by Application

  • 13 Key Players Analysis

    • 13.1 American Lung Association
      • 13.1.1 American Lung Association Company Information
      • 13.1.2 American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications
      • 13.1.3 American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 American Lung Association Main Business Overview
      • 13.1.5 American Lung Association Latest Developments
    • 13.2 Roche
      • 13.2.1 Roche Company Information
      • 13.2.2 Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications
      • 13.2.3 Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Roche Main Business Overview
      • 13.2.5 Roche Latest Developments
    • 13.3 Genentech
      • 13.3.1 Genentech Company Information
      • 13.3.2 Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications
      • 13.3.3 Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 Genentech Main Business Overview
      • 13.3.5 Genentech Latest Developments
    • 13.4 Fierce Pharma
      • 13.4.1 Fierce Pharma Company Information
      • 13.4.2 Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications
      • 13.4.3 Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Fierce Pharma Main Business Overview
      • 13.4.5 Fierce Pharma Latest Developments

  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.